In this randomized trial, standard treatment of rifampin and isoniazid for 24 weeks plus pyrazinamide and ethambutol for the initial 8 weeks was compared with an initial treatment of bedaquiline–linezolid for 8 weeks, extended treatment for persistent clinical disease, monitoring after treatment, and retreatment for relapse. The shorter approach was determined to be non-inferior.